{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T16:02:19Z","timestamp":1781539339749,"version":"3.54.5"},"reference-count":41,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T00:00:00Z","timestamp":1669161600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.clml.2022.11.009","type":"journal-article","created":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T10:34:12Z","timestamp":1669372452000},"page":"e107-e116","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Interim FDG18-PET SUVmax Variation Adds Prognostic Value to Deauville 5-Point Scale in the Identification of Patients with Ultra-High-Risk Diffuse Large B Cell Lymphoma"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7641-175X","authenticated-orcid":false,"given":"Sara","family":"Duarte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Roque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiago","family":"Saraiva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Afonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e1rbara Almeida","family":"Marques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla Barros","family":"Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dulcelena","family":"Neves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Catarina","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gracinda","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Augusta","family":"Cipriano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catarina","family":"Geraldes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lenka","family":"Ruzickova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Pedro","family":"Carda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8633-6941","authenticated-orcid":false,"given":"Mar\u00edlia","family":"Gomes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2022.11.009_bib0001","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41408-018-0054-y","article-title":"The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion","volume":"8","author":"Barbui","year":"2018","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2022.11.009_bib0002","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","article-title":"Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte","volume":"116","author":"Coiffier","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.11.009_bib0003","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1200\/JCO.2005.05.1003","article-title":"Rituximab-CHOP Versus CHOP alone or with maintenance Rituximab in older patients with diffuse large B-Cell Lymphoma","volume":"24","author":"Habermann","year":"2006","journal-title":"J Clinic Oncol"},{"key":"10.1016\/j.clml.2022.11.009_bib0004","doi-asserted-by":"crossref","first-page":"5027","DOI":"10.1200\/JCO.2005.09.137","article-title":"Introduction of combined CHOP plus Rituximab therapy dramatically improved outcome of diffuse large B-Cell Lymphoma in British Columbia","volume":"23","author":"Sehn","year":"2005","journal-title":"JClinic Oncol"},{"key":"10.1016\/j.clml.2022.11.009_bib0005","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.beha.2018.07.014","article-title":"Management of relapsed\/refractory DLBCL","volume":"31","author":"Sarkozy","year":"2018","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.clml.2022.11.009_bib0006","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.clml.2022.11.009_bib0007","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMoa012914","article-title":"The use of Molecular profiling to predict survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma","volume":"346","author":"Rosenwald","year":"2002","journal-title":"New England J Med"},{"key":"10.1016\/j.clml.2022.11.009_bib0008","doi-asserted-by":"crossref","first-page":"13520","DOI":"10.1073\/pnas.0804295105","article-title":"Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways","volume":"105","author":"Lenz","year":"2008","journal-title":"ProceedNational Acad Sci"},{"key":"10.1016\/j.clml.2022.11.009_bib0009","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1182\/blood-2014-05-578963","article-title":"Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis","volume":"124","author":"Petrich","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.11.009_bib0010","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1182\/blood-2017-12-820605","article-title":"High-grade B-cell lymphoma with MYC and BCL2 and\/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology","volume":"131","author":"Scott","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.11.009_bib0011","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.11.009_bib0012","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of hodgkin and non-hodgkin lymphoma: The lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"JClinic Oncol"},{"key":"10.1016\/j.clml.2022.11.009_bib0013","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1080\/10428190903040048","article-title":"Report on the First International Workshop on interim-PET scan in lymphoma","volume":"50","author":"Meignan","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2022.11.009_bib0014","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1016\/j.ejrad.2016.08.011","article-title":"Proportion of false-positive lesions at interim and end-of-treatment FDG-PET in lymphoma as determined by histology: Systematic review and meta-analysis","volume":"85","author":"Adams","year":"2016","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.clml.2022.11.009_bib0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0149072","article-title":"Inter-Reader reliability of Early FDG-PET\/CT response assessment using the Deauville Scale after 2 Cycles of Intensive Chemotherapy (OEPA) in Hodgkin's Lymphoma","volume":"11","author":"Kluge","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.clml.2022.11.009_bib0016","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2967\/jnumed.120.244145","article-title":"Interim PET evaluation in diffuse large b-cell lymphoma using published recommendations: Comparison of the deauville 5-point scale and the \u0394SUVmax method","volume":"62","author":"Rekowski","year":"2021","journal-title":"J Nuclear Med"},{"key":"10.1016\/j.clml.2022.11.009_bib0017","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1007\/s00259-013-2435-6","article-title":"An international confirmatory study of the prognostic value of early PET\/CT in diffuse large B-cell lymphoma: Comparison between Deauville criteria and \u0394sUVmax","volume":"40","author":"Itti","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.clml.2022.11.009_bib0018","doi-asserted-by":"crossref","first-page":"5012","DOI":"10.1002\/cam4.2404","article-title":"Interim PET\/CT based on visual and semiquantitative analysis predicts survival in patients with diffuse large B-cell lymphoma","volume":"8","author":"Li","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.clml.2022.11.009_bib0019","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1200\/JCO.2017.76.8093","article-title":"Positron Emission Tomography-Guided Therapy of aggressive Non-Hodgkin Lymphomas (PETAL): A multicenter, randomized Phase III Trial","volume":"36","author":"D\u00fchrsen","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.11.009_bib0020","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1200\/JCO.2018.78.9362","article-title":"Response-Adapted Therapy in Aggressive Lymphoma: not yet ready for clinical care","volume":"36","author":"Merryman","year":"2018","journal-title":"J Clinic Oncol"},{"key":"10.1016\/j.clml.2022.11.009_bib0021","unstructured":"Sch\u00f6der H, Wilson W. Prognostic value of interim FDG-PET in Diffuse Large Cell Lymphoma: results from the CALGB 50303 Clinical Trial. doi:10.1182\/blood.2019003277\/1719116\/blood.2019003277.pdf"},{"key":"10.1016\/j.clml.2022.11.009_bib0022","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0211649","article-title":"Comparison of therapeutic evaluation criteria in FDG-PET\/CT in patients with diffuse large-cell B-cell lymphoma: Prognostic impact of tumor\/liver ratio","volume":"14","author":"Toledano","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.clml.2022.11.009_bib0023","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/blood-2010-12-327767","article-title":"SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma","volume":"118","author":"Casasnovas","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.11.009_bib0024","first-page":"1626","article-title":"Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis","volume":"48","author":"Lin","year":"2007","journal-title":"JNuclear Med"},{"key":"10.1016\/j.clml.2022.11.009_bib0025","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","article-title":"Role of imaging in the staging and response assessment of lymphoma: Consensus of the international conference on malignant lymphomas imaging working group","volume":"32","author":"Barrington","year":"2014","journal-title":"J Clinic Oncol"},{"key":"10.1016\/j.clml.2022.11.009_bib0026","doi-asserted-by":"crossref","unstructured":"Cheson BD, Ansell S, Schwartz L, et\u00a0al. Refinement of the Lugano classification lymphoma response criteria in the era of immunomodulatory therapy. 2016. doi:10.1182\/blood-2016-05","DOI":"10.1182\/blood-2016-05-718528"},{"key":"10.1016\/j.clml.2022.11.009_bib0027","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1053\/j.semnuclmed.2017.09.002","article-title":"Interim FDG-PET imaging in Lymphoma","volume":"48","author":"Gallamini","year":"2018","journal-title":"Semin Nucl Med"},{"key":"10.1016\/j.clml.2022.11.009_bib0028","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/ejh.13684","article-title":"Predicting primary treatment failure using interim FDG-PET scanning in diffuse large B-cell lymphoma","volume":"107","author":"Wight","year":"2021","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2022.11.009_bib0029","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1093\/annonc\/mdw419","article-title":"ESMO consensus conference on malignant lymphoma: general perspectives and recommendations for prognostic tools in mature B-cell lymphomas and chronic lymphocytic leukaemia","volume":"27","author":"Ladetto","year":"2016","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.clml.2022.11.009_bib0030","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00259-018-4103-3","article-title":"Predictive value of interim positron emission tomography in diffuse large B-cell lymphoma: a systematic review and meta-analysis","volume":"46","author":"Burggraaff","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.clml.2022.11.009_bib0031","doi-asserted-by":"crossref","first-page":"386","DOI":"10.2967\/jnumed.110.082586","article-title":"18F-FDG PET\/CT for early response assessment in diffuse large B-Cell Lymphoma: poor predictive value of International Harmonization Project Interpretation","volume":"52","author":"Cashen","year":"2011","journal-title":"J Nuclear Med"},{"key":"10.1016\/j.clml.2022.11.009_bib0032","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1200\/JCO.2009.26.5942","article-title":"Risk-adapted dose-dense Immunochemotherapy determined by Interim FDG-PET in advanced-Stage Diffuse Large B-Cell Lymphoma","volume":"28","author":"Moskowitz","year":"2010","journal-title":"JClinic Oncol"},{"key":"10.1016\/j.clml.2022.11.009_bib0033","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1182\/blood-2011-06-359943","article-title":"Interim 18-FDG-PET\/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP","volume":"119","author":"Pregno","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.11.009_bib0034","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1093\/annonc\/mdf256","article-title":"Early restaging positron emission tomography with 18F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma","volume":"13","author":"Spaepen","year":"2002","journal-title":"Annals Oncol"},{"key":"10.1016\/j.clml.2022.11.009_bib0035","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1200\/JCO.2001.19.2.414","article-title":"Prognostic value of Positron Emission Tomography (PET) with Fluorine-18 Fluorodeoxyglucose ([18 F]FDG) after First-Line Chemotherapy in Non-Hodgkin's Lymphoma: Is [18 F]FDG-PET a valid alternative to conventional diagnostic methods?","volume":"19","author":"Spaepen","year":"2001","journal-title":"JClinic Oncol"},{"key":"10.1016\/j.clml.2022.11.009_bib0036","doi-asserted-by":"crossref","first-page":"527","DOI":"10.2967\/jnumed.108.057703","article-title":"Prognostic value of interim 18F-FDG PET in patients with diffuse large B-Cell Lymphoma: SUV-Based assessment at 4 cycles of Chemotherapy","volume":"50","author":"Itti","year":"2009","journal-title":"J Nuclear Med"},{"key":"10.1016\/j.clml.2022.11.009_bib0037","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1200\/JCO.2014.58.9846","article-title":"Final results of a prospective evaluation of the predictive value of interim positron emission tomography in patients with diffuse large B-cell lymphoma treated with R-CHOP-14 (SAKK 38\/07)","volume":"33","author":"Mamot","year":"2015","journal-title":"J ClinicOncol"},{"key":"10.1016\/j.clml.2022.11.009_bib0038","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.3109\/10428194.2012.677535","article-title":"Report on the third international workshop on interim positron emission Tomography in Lymphoma held in Menton, France, 26\u201327 September 2011 and Menton 2011 consensus","volume":"53","author":"Meignan","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2022.11.009_bib0039","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ejca.2019.09.027","article-title":"Dynamic risk assessment based on positron emission tomography scanning in diffuse large B-cell lymphoma: Post-hoc analysis from the PETAL trial","volume":"124","author":"Schmitz","year":"2020","journal-title":"Eur J Cancer"},{"issue":"7","key":"10.1016\/j.clml.2022.11.009_bib0040","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1007\/s00259-016-3315-7","article-title":"Combination of baseline metabolic tumour volume and early response on PET\/CT improves progression-free survival prediction in DLBCL","volume":"43","author":"Mikhaeel","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.clml.2022.11.009_bib0041","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s12185-019-02690-2","article-title":"Interim PET\/CT in diffuse large B-cell lymphoma may facilitate identification of good-prognosis patients among IPI-stratified patients","volume":"110","author":"Nyilas","year":"2019","journal-title":"Int J Hematol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022017438?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022017438?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:41:46Z","timestamp":1761871306000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265022017438"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S2152265022017438"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2022.11.009","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interim FDG18-PET SUVmax Variation Adds Prognostic Value to Deauville 5-Point Scale in the Identification of Patients with Ultra-High-Risk Diffuse Large B Cell Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2022.11.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}